EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Adjuvant Use of Pembrolizumab for Stage III Melanoma in a Real-World Setting in Europe

Michael Weichenthal iD, Joanna Mangana, Iva Gavrilova, Iwona Lugowska iD, Gergana Krumova Shalamanova, Lidija Kandolf iD, Vanna Chiarion-Sileni, Peter Mohr, Teodora Sotirova Karanikolova, Pawel Teterycz iD, Enrique Espinosa, Philipp Schnecko und 11 weitere

Cancers · 22.10.2024 · 16 (21) · 3558

DOI: 10.3390/cancers16213558 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 22.10.2024. Verfasst von Michael Weichenthal und 22 weiteren Autor:innen. Beteiligte Einrichtung: Skin Cancer Center Kiel, University Hospital Schleswig-Holstein, 24105 Kiel, Germany. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Merck & Co., Inc., Rahway, NJ, USA, Merck Sharp & Dohme LLC, Merck & Co., Inc., Rahway, NJ, USA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Although data on patients treated with pembrolizumab are available from clinical trials and single-country real-world reports, to our knowledge no multi-country real-world studies have investigated the use of pembrolizumab as an adjuvant treatment for stage III melanoma.

Methods

We used the European Melanoma Registry (EUMelaReg), a disease entity-based registry specific for melanoma, to examine treatment and outcomes for adult patients with stage III melanoma with lymph node involvement who had complete resection and received adjuvant treatment with pembrolizumab. The primary objectives were to describe the demographic and clinical characteristics of the included patients as well as time on adjuvant pembrolizumab treatment (TOT), real-world recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) from adjuvant pembrolizumab initiation. Secondary objectives were time to next treatment (TTNT) after adjuvant use of pembrolizumab, next-line therapy for stage III and unresectable stage IV melanoma and overall survival (OS) from initiation of pembrolizumab.

Results

Patients were stratified according to age, sex, BRAF status, number of positive lymph nodes and disease substage. Median TOT was 11.1 (9.2–11.5) months, median RFS was 29.6 [18.7–not reached (NR)] months and median DMFS was 32.4 (22.7–NR) months. TTNT was 29.9 (22.2–NR) months, while median OS was not reached.

Conclusions

The results of this study offer insights into the real-world use of pembrolizumab as an adjuvant therapy for melanoma in Europe.

Schlagwörter

Stichwörter der Autor:innen

EUMelaRegadjuvant pembrolizumabcutaneous melanomamelanomareal-worldstage III

Autor:innen und Institutionen

  • Skin Cancer Center Kiel, University Hospital Schleswig-Holstein, 24105 Kiel, Germany.
  • University Hospital of Zurich, 8091 Zurich, Switzerland.
  • National Oncology Hospital Sofia, g.k. Darvenitsa, 1756 Sofia, Bulgaria.
  • Instytut im. Marii Skłodowskiej-Curie, 02-781 Warsaw, Poland.
  • Complex Oncology Center Plovdiv, 4004 Plovdiv, Bulgaria.
  • Military Medical Academy (CSEEMEG), 11000 Belgrade, Serbia.

ORCID-Profile: Michael Weichenthal, Iwona Lugowska, Lidija Kandolf, Pawel Teterycz, Phil Cheng, Marc Bender, Helen Gogas, Ivan Marquez Rodas, Piotr Rutkowski, Dirk Schadendorf, Reinhard Dummer

Förderung

  • Merck & Co., Inc., Rahway, NJ, USA
  • Merck Sharp & Dohme LLC
  • Merck & Co., Inc., Rahway, NJ, USA

Zitieren

APA

Weichenthal, M., Mangana, J., Gavrilova, I., Lugowska, I., Shalamanova, G. K., Kandolf, L., Chiarion-Sileni, V., Mohr, P., Karanikolova, T. S., Teterycz, P., Espinosa, E., Schnecko, P., Cheng, P., Bender, M., Jiang, S., Burke, T., Ascierto, P. A., Gogas, H., Rodas, I. M., …, & For The EUMelaReg Consortium (2024). Adjuvant Use of Pembrolizumab for Stage III Melanoma in a Real-World Setting in Europe. Cancers, 16(21), 3558. https://doi.org/10.3390/cancers16213558

Vancouver

Weichenthal M, Mangana J, Gavrilova I, Lugowska I, Shalamanova GK, Kandolf L, et al. Adjuvant Use of Pembrolizumab for Stage III Melanoma in a Real-World Setting in Europe. Cancers. 2024;16(21):3558. doi:10.3390/cancers16213558

BibTeX
@article{Weichenthal2024,
  author = {Weichenthal, Michael and Mangana, Joanna and Gavrilova, Iva and Lugowska, Iwona and Shalamanova, Gergana Krumova and Kandolf, Lidija and Chiarion-Sileni, Vanna and Mohr, Peter and Karanikolova, Teodora Sotirova and Teterycz, Pawel and Espinosa, Enrique and Schnecko, Philipp and Cheng, Phil and Bender, Marc and Jiang, Shan and Burke, Thomas and Ascierto, Paolo Antonio and Gogas, Helen and Rodas, Ivan Marquez and Rutkowski, Piotr and Schadendorf, Dirk and Dummer, Reinhard and For The EUMelaReg Consortium},
  title = {Adjuvant Use of Pembrolizumab for Stage III Melanoma in a Real-World Setting in Europe},
  journal = {Cancers},
  year = {2024},
  volume = {16},
  number = {21},
  pages = {3558},
  doi = {10.3390/cancers16213558}
}
Kostenlos starten →